Macrophage reprogramming—rather than depletion—is efficacious in a specific subset of colorectal tumor models (original) (raw)

Mohamed, N. E. et al. (2023) Macrophage reprogramming—rather than depletion—is efficacious in a specific subset of colorectal tumor models.Research Square, (doi: 10.21203/rs.3.rs-3212822/v1)

Abstract

Despite the abundance of macrophages in colorectal cancer (CRC), macrophage-targeted therapy has not demonstrated significant clinical benefit. Here, we show that macrophage populations differ across the consensus molecular subtypes (CMS) of CRC and report the first preclinical study of macrophage targeting using mouse models stratified by CMS class. Whereas pan-macrophage ablation, using a CSF1R-inhibitor, lacked efficacy across CMS classes, genetic deletion of inflammatory chemokine receptors (iCCRs) reprogrammed macrophages towards an anti-tumorigenic phenotype, curtailing tumorigenesis in models of CMS1 CRC. We identify an iCCR-independent anti-tumorigenic antigen-presenting macrophage population necessary for therapeutic efficacy. We further show that individual targeting of the CCR1, CCR2, and CCR5 receptors on CRC macrophages lacks benefit, whereas their combined targeting holds promise. We propose that selective targeting of immunosuppressive macrophage populations, whilst sparing antigen-presenting subsets, should be considered when trialling macrophage-targeted therapies.

Item Type: Articles (Pre-print)
Additional Information: O.J.S. and his lab members were supported by CRUK grants [A28223—ACRCelerate CRUK Accelerator Award, A21139, A12481, A17196, A31287 and DRCQQRMay21\100002]. In addition, O.J.S. received funding from AstraZeneca and N.E.M. was supported by a research collaboration agreement with AstraZeneca to perform the AZD7507 experiments. O.J.S. and S.J.L. and their labs were supported by CRUK grant DRCNPG-Jun22\100002. GJG and his lab were supported by grants from the Wellcome Trust (217093/Z/19/Z) and the MRC (MR/V010972/1). J.E. was funded by CRUK CTRQQR-2021/100006. K.P. was funded by the Chief Scientific Office grant TCS/22/02. P.H. was funded by CRUK RRNPSF-JUL21/1D100010. E.J.M. was funded by the Lee Placito Medical Research Fund (University of Oxford) and OxCODE Funding Scheme (University of Oxford). Research in ADG lab is supported by Research Foundation Flanders (FWO) (Fundamental Research Grant, G0B4620N; Excellence of Science/EOS grant, 30837538), KU Leuven (C1 grant, C14/19/098 and C3 grant, C3/21/037), Kom op Tegen Kanker (KOTK/2018/11509/1) and VLIR-UOS (iBOF grant, iBOF/21/048, for ‘MIMICRY’ consortium).
Keywords: Colorectal cancer (CRC), consensus molecular subtypes (CMS), inflammatory chemokine receptors (iCCR), macrophages, colony stimulating factor 1 receptor (CSF1R), single cell RNA sequencing, preclinical GEMM models, tumor immune microenvironment (TIME), repolarisation, immunotherapy.
Status: Published
Refereed: No
Glasgow Author(s) Enlighten ID: Pennel, Dr Kathryn and Ehssan Mohamed, Dr Noha and Edwards, Professor Joanne
Authors: Mohamed, N. E., Amirkhah, R., Lavaud, X.-C., Gilroy, K., Bartolini, R., Mulholland, E. J., Garg, A. D., Pennel, K., Jackstadt, R., Ridgway, R. A., Nixon, C., Hatthakarnku, P., Campbell, A. D., Leedham, S. J., Edwards, J., Dunne, P. D., Barry, S. T., Graham, G. J., and Sansom, O. J.
College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name: Research Square
Copyright Holders: Copyright © 2023 The Authors
First Published: First published in Research Square 03 Aug 2023
Publisher Policy: Reproduced under a Creative Commons license

University Staff: Request a correction | Enlighten Editors: Update this record

Deposit and Record Details

ID Code: 376781
Depositing User: Dr Noha Ehssan Mohamed
Datestamp: 19 Jan 2026 10:12
Last Modified: 20 Jan 2026 02:32
Date of first online publication: 3 August 2023
Date Deposited: 19 January 2026
Data Availability Statement: Yes